NCT06816498View on ClinicalTrials.gov

Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Autosomal Dominant Leukodystrophy
Interventions
DRUG

nL-LMNB1-001

Personalized antisense oligonucleotide

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Mayo Clinic

OTHER

lead

n-Lorem Foundation

OTHER

NCT06816498 - Personalized Antisense Oligonucleotide Therapy for A Single Participant With LMNB1 Mutation Associated Autosomal Dominant Leukodystrophy (ADLD) | Biotech Hunter | Biotech Hunter